Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner ...

This page features the latest news about the Kyverna Therapeutics stock. KYTX stock touches 52-week low at $2.78 amid sharp annual decline Kyverna Therapeutics Inc. (KYTX) stock has reached a new ...

NASDAQ KYTX opened at $3.03 on Thursday. Kyverna Therapeutics has a 1-year low of $2.64 and a 1-year high of $30.60. The business has a 50 day simple moving average of $3.63 and a two-hundred day ...

Kyverna Therapeutics, Inc. (KYTX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

H.C. Wainwright has maintained its Neutral rating and $7.00 price target for Kyverna Therapeutics Inc (NASDAQ: KYTX) following the company's recent presentation at the European ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to Kyverna's initial public ...

IF YOU ARE AN INVESTOR WHO LOST MONEY ON KYVERNA THERAPEUTICS ... and published an investor presentation disclosing adverse data regarding one of its clinical trials, despite having previously ...

Kyverna Therapeutics, Inc. has a 52-week low of $3.02 and a 52-week high of $35.06. The business’s 50 day moving average is $4.00 and its two-hundred day moving average is $5.48.

Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ ...